ArticleJournal of substance abuse treatment2020
Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.
Article in Journal of substance abuse treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Correlates of post-hospitalization naltrexone adherence for alcohol use disorder.Drug and alcohol dependence · 2024Trial
- Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Facilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial.Journal of addiction medicineTrial
- Policy and practice recommendations for residential addiction treatment: a qualitative investigation on increasing equity in treatment for Black patients.Addiction science & clinical practice · 2026Article
- Cognitive function and mortality among persons aging with HIV and injection drug use.AIDS (London, England) · 2025Article
- Alcohol Use and Its Associations With Frailty, Fractures, and Falls Among Older Adults With HIV.Alcohol research : current reviews · 2025Review
- Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV.AIDS and behavior · 2024Article
- Medications for Alcohol Use Disorder: Rates and Predictors of Prescription Order and Fill in Outpatient Settings.Journal of general internal medicine · 2024Article
- Disparities in Treatment for Alcohol Use Disorder Among All of Us Participants.The American journal of psychiatry · 2024Article
- Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden.Addiction science & clinical practice · 2024Article
- Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium.The International journal on drug policy · 2024Article
- Contingency management with stepped care for unhealthy alcohol use among individuals with HIV: Protocol for a randomized controlled trial.Contemporary clinical trials · 2023Article
- Patients' perspectives of medications for addiction treatment in HIV clinics: A qualitative study.Journal of substance abuse treatment · 2022Article
- Medication prescribing for alcohol use disorders during alcohol-related encounters in a Colorado regional healthcare system.Alcoholism, clinical and experimental research · 2022Article
- Longitudinal analysis of the prevalence and correlates of heavy episodic drinking and self-reported opioid use among a national cohort of patients with HIV.Alcoholism, clinical and experimental research · 2022Article
- Chronic Alcohol Exposure Among People Living with HIV Is Associated with Innate Immune Activation and Alterations in Monocyte Phenotype and Plasma Cytokine Profile.Frontiers in immunology · 2022Article
- Treatment for alcohol use disorder among persons with and without HIV in a clinical care setting in the United States.Drug and alcohol dependence · 2021Article
- Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation.Journal of acquired immune deficiency syndromes (1999) · 2021Article
- Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis.Drug and alcohol dependence · 2020Article
- Working with HIV clinics to adopt addiction treatment using implementation facilitation (WHAT-IF?): Rationale and design for a hybrid type 3 effectiveness-implementation study.Contemporary clinical trials · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
introductionInfrequent use of and poor retention on evidence-based medications for alcohol use disorder (MAUD) represent a treatment gap, particularly among people living with HIV (PLWH). We examined predictors of MAUD initiation and retention across HIV status.
methodsFrom Veterans Aging Cohort Study (VACS) data, we identified new alcohol use disorder (AUD) diagnoses from 1998 to 2015 among 163,339 individuals (50,826 PLWH and 112,573 uninfected, matched by age, sex, and facility). MAUD initiation was defined as a prescription fill for naltrexone, acamprosate or disulfiram within 30 days of a new diagnosis. Among those who initiated, retention was defined as filling medication for ≥80% of days over the following six months. We used multivariable logistic regression to assess patient- and facility-level predictors of AUD medication initiation across HIV status.
resultsAmong 10,603 PLWH and 24,424 uninfected individuals with at least one AUD episode, 359 (1.0%) initiated MAUD and 49 (0.14%) were retained. The prevalence of initiation was lower among PLWH than those without HIV (adjusted odds ratio [AOR] 0.66, 95% confidence interval [CI] 0.51-0.85). Older age (for PLWH: AOR 0.78, 95% CI 0.61-0.99; for uninfected: AOR 0.70, 95% CI 0.61-0.80) and black race (for PLWH: AOR 0.63, 95% CI 0.0.49-0.1.00; for uninfected: AOR 0.63, 95% CI 0.48-0.83), were associated with decreased odds of initiation for both groups. The low frequency of retention precluded multivariable analyses for retention.
conclusionsFor PLWH and uninfected individuals, targeted implementation strategies to expand MAUD are needed, particularly for specific subpopulations (e.g. black PLWH).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.